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Conclusions
Bridging the drug-mediated reduction of Breg cell numbers in vivo with the requirements of Breg cells for long-term transplant success remains an as yet unresolved task for therapeutic intervention.
Further larger cohort studies that evaluate the effect of different treatment regimen on defined lymphocyte subpopulations are warranted.
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INTRODUCTION
Organ transplantation is the treatment of choice for patients with end-stage organ failure. Its success critically depends on efficient immunosuppressive drug regimen to avoid allograft rejection. Effector T cells have long been recognized as critical mediators of rejection and regulatory T cells (Treg) as mediators of tolerance (1) . However, literature suggests that B cell mediated immunity has a major contribution in the prevention of transplant rejection as well (2) . This is especially evident during spontaneous tolerance (also called operational tolerance), defined as the development of tolerance after the complete withdrawal of immunosuppressants in a rare group of transplanted individuals.
Spontaneous tolerant individuals present a B cell gene expression signature and preserve numbers of total B cells similar to healthy individuals (3) (4) (5) . to be enriched for IL10 expression (7, 10) .
Studies on B cell depletion during transplant induction therapy and transplant tolerance suggest a suppressive function and a crosstalk between Treg and Breg subpopulations in transplantation (11).
However, little is known on how both cell types are influenced by long-term treatment with immunosuppressive drugs. A very recent study has prospectively followed a cohort of kidney transplant (KT) recipients under tacrolimus for over one year post transplantation. Patients with high transitional B cell rates experienced reduced rejection episodes (12) . Furthermore, across-sectional study covering 10 years post transplantation demonstrated that Breg cells contribute to the maintenance of graft survival in patients treated with calcineurin inhibitors (CNI) (13) . Treatment of KT patients with belatacept, a novel T cell co-stimulation blocker, led to an increase of Breg and Treg cell numbers when compared to a standard CNI treatment (14, 15) . It is unclear however how other
immunosuppressive drugs in clinical practice affect both regulatory cell subsets and whether these contribute to tolerance during very long time periods after transplantation.
OBJECTIVE
The present study investigated the effect of CNI and mammalian target of rapamycin (mTOR) inhibitor therapies on Breg and Treg cell numbers in KT recipients with stable graft function. Breg cells described as IL10-secreting B cells (7) 
MATERIALS AND METHODS
Patients and inclusion criteria
We recruited KT recipients with stable graft function who attended the Nephrology Department of the Hospital del Mar (Barcelona, Spain) between December 2012 and February 2014. For immune phenotyping by flow cytometry, a total of 20 mL blood was drawn from each patient into lithiumheparinized tubes. Complete blood counts (Haemogram) were determined in parallel to derive absolute cell numbers. The collected patients' data were: gender, age, kidney origin, CMV disease, drug-therapeutic profile, years after transplantation, estimated glomerular filtration rate (eGFR) and proteinuria/creatinine ratio. Ethical approval for this study was obtained from the corresponding Ethics Committee. All the study participants gave written informed consent before entering the study.
A C C E P T E D M A N U S C R I P T counted with an inverted microscope using trypan blue. Flow cytometry data analysis was performed using FlowJo 9.44 software (TreeStar, Inc., Ashland, OR, USA) following the gating strategy shown in Figure 1A -B.
Isolation of peripheral blood mononuclear cells (PBMCs)
Quantification of IL10-secreting B cells (B10), CD19
Statistical data analysis
Comparison of different cell populations between groups of patients was performed using the MannWhitney U-test analysis. Differences were considered significant when p-values were lower than 0.05. Table 1 . No significant differences on age and gender were observed between KT patients and healthy controls. Due to the inclusion of patients under classical CNI therapies, the time frame since transplantation was higher in this group than the one receiving mTOR inhibitors (p=0.082). Figure 1D ). The numbers of IL10-producing B cells and transitional B cells were significantly decreased in CNI-and mTOR inhibitortreated patients with respect to healthy controls ( Figure 1E ; p=0.001 and p=0.011 for IL10-producing B Figure 1E ; p=0.022 and p=0.0003, respectively). However, these differences between the patient groups may be attributed to the time frame since transplantation, which was higher in the CNI group with respect to the one receiving mTOR inhibitors. Thus, in order to test whether the observed significant differences of transitional B and Treg cell numbers between the treated groups were influenced by years post transplantation, a multivariate analysis was performed for these two subsets adjusting for years post transplantation, treatment regimen and eGFR (mL/min). It revealed that the number of Breg cells correlated with years' post transplantation irrespective of CNI or mTOR inhibitor treatment. Nevertheless, only mTOR inhibitor treatment rather than CNI treatment resulted in high Treg cell numbers ( Table 2) . Thus, during mTOR inhibitor treatment, a reduction of Breg cells may be compensated by maintenance or even an increase of Tregs.
A C C E P T E D
CNI and mTOR inhibitors differentially affect Breg and Treg cell numbers in long-term immunosuppressed KT recipients
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DISCUSSION
Given the increasing evidences of a beneficial effect of regulatory lymphocyte subsets for transplantation success (5, 12, 13, 20, 21) , the impact of different immunosuppressive drug regimen on these cells is insufficiently studied. Especially simultaneous evaluations of Breg and Treg cells are rare.
Here Limitations of our study should be mentioned. First, the groups of patients according to their treatment regimen (CNI versus mTOR inhibitors) are different in terms of years after transplantation.
This is due to the inclusion of patients under the classical drugs targeting calcineurin activity.
Nonetheless, consistent results were obtained performing a multivariate analysis. Second, the number of patients included is limited. Third, our cohort of KT patients is not prospectively followed over time and does not included individuals with chronic rejection. However, as a pilot study it provides sufficient evidence that it would be interesting to move forward in this matter. In line with this, two of our patients lost their grafts and presented very high B effector/Breg ratios (Beff/Breg ratio: 141.8 and 201.2; median: 20.53) (25) . These observations call for studying and following-up larger matched case-
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12 control cohorts to better evaluate lymphocyte subsets as biomarker for individualized therapies and outcome.
Conclusions
In conclusion, (i) a differential effect of CNI and mTOR inhibitor treatment after KT on Breg and Treg lymphocyte subsets is described and (ii) transitional B cells and long-term transplantation success seem to correlate for both treatment regimens. However, the knowledge gap between the direct drug effect of lowering Breg cells with transplantation success that correlates with high Breg cell numbers remains, and requests further investigations with larger patient cohorts. Eventually this will lead to a better definition of personalized transplantation therapies. 
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